Lipocine (LPCN) EBIAT (2016 - 2025)
Lipocine (LPCN) has disclosed EBIAT for 13 consecutive years, with -$3.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 43.63% year-over-year to -$3.2 million, compared with a TTM value of -$5.5 million through Sep 2025, down 34.99%, and an annual FY2024 reading of $8352.0, up 100.05% over the prior year.
- EBIAT was -$3.2 million for Q3 2025 at Lipocine, down from -$2.2 million in the prior quarter.
- Across five years, EBIAT topped out at $12.6 million in Q4 2021 and bottomed at -$6.8 million in Q2 2021.
- Average EBIAT over 5 years is -$1.8 million, with a median of -$2.6 million recorded in 2022.
- The sharpest move saw EBIAT soared 379.83% in 2021, then tumbled 176.07% in 2023.
- Year by year, EBIAT stood at $12.6 million in 2021, then tumbled by 117.66% to -$2.2 million in 2022, then dropped by 2.35% to -$2.3 million in 2023, then soared by 178.09% to $1.8 million in 2024, then plummeted by 278.82% to -$3.2 million in 2025.
- Business Quant data shows EBIAT for LPCN at -$3.2 million in Q3 2025, -$2.2 million in Q2 2025, and -$1.9 million in Q1 2025.